Maze Therapeutics Inc Reports Q3 2026 Net Loss of $48 Million, EPS of $0.79 Misses Estimates
Clinical-Stage Biotech Narrows Nine-Month Loss While Cash Position Rises to $477 Million Related Stocks: MAZE ,
Clinical-Stage Biotech Narrows Nine-Month Loss While Cash Position Rises to $477 Million Related Stocks: MAZE ,